Company: LIMN
Filing Date: 2025-06-02
Form Type: 8-K/A
Source: 0001104659-25-055078
Chunk: 29

Company: Liminatus Pharma, Inc.
Filing Date: 2025-06-02
Form: 8-K/A
Chunk 29
---
holder of record.
Such holder numbers do not include Depository Trust Company participants or beneficial owners holding shares through nominee names.

Indemnification of Directors and Officers

The description of the indemnification
arrangements with the Company’s directors and officers is contained in Item 1.01 of this Report and in the Proxy Statement in the
section titled “Limitation on Liability and Indemnification of Directors and Officers” beginning on page 212 of
the Proxy Statement/Prospectus, which is incorporated herein by reference.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Information about changes
in accountants on accounting and financial disclosure is set forth under Item 4.01 of this Report, which is incorporated herein by reference.

Financial Statements, Supplementary Data and Exhibits

Reference is made to the disclosure
set forth under Item 9.01 of this Report concerning the Company’s financial statements and supplementary information, which is incorporated
herein by reference.

The information set forth
in Items 9.01(a), (b) and (d) of this Amendment No. 1 is incorporated herein by reference.

Quantitative and Qualitative Disclosures about Market Risk

The Company is a smaller reporting
company as defined by Rule 12b-2 of the Exchange Act and is not required to provide the information otherwise required under this
item.

<div align='center'>18</div>

Item 9.01. Financial Statements and Exhibits.

(a) Financial Statements of Businesses Acquired.

The audited financial statements
of ParentCo for the fiscal years ended December 31, 2024 and 2023, the related notes and report of independent registered public
accounting firm are filed herewith as Exhibit 99.1 and are incorporated herein by reference.

The audited financial statements
of Liminatus for the fiscal years ended December 31, 2024 and 2023, the related notes and report of independent registered public
accounting firm are filed herewith as Exhibit 99.2 and are incorporated herein by reference.

The unaudited financial statements
of Liminatus for the three months ended March 31, 2025 and 2024 and the related notes are filed herewith as Exhibit 99.5 and are
incorporated herein by reference.

The unaudited financial statements
of Iris for the three months ended March 31, 2025 and 2024 and the related notes are filed herewith as Exhibit 99